GENELUX Corp
GNLX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GNLX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GNLX
Genelux Corp (GNLX) is a clinical-stage biopharmaceutical company developing oncolytic vaccinia virus (VACV) immunotherapies for multiple tumor types, leveraging its proprietary CHOICE platform.
Key risk: Cash runway limited
BioSniper Score
Based on 6 of 6 signals
Market Cap
$120.4M
Cash Runway
8.5 moLead Asset
olvi-vec (Phase 1/Phase 2)Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 5 clinical trials · 2 catalysts for GENELUX Corp.
Genelux Corp (GNLX) is a clinical-stage biopharmaceutical company developing oncolytic vaccinia virus (VACV) immunotherapies for multiple tumor types, leveraging its proprietary CHOICE platform.
- Genelux focuses on oncolytic VACV immunotherapies engineered via its CHOICE platform for multiple tumor types [sec_mda · as of 2026-08-13].
- Cash & equivalents of $9.2M as of 2026-06-30 [sec].
- Net income of -$9.5M as of 2026-06-30 [sec].
- Shareholders' equity of $11.5M as of 2026-06-30 [sec].
- Cash runway is estimated to fund operations into the first quarter of 2027 [sec_mda · as of 2026-08-13].
What works
- Proprietary CHOICE platform enables development of an extensive library of engineered oncolytic VACV immunotherapeutic candidates [sec_mda · as of 2026-08-13].
- Product candidates have potential utility in multiple tumor types via physician-preferred administration routes including regional, local, and systemic delivery [sec_mda · as of 2026-08-13].
- Pipeline supported by extensive clinical and preclinical data, targeting high unmet medical needs [sec_mda · as of 2026-08-13].
What to weigh
- No revenue from product sales; company will not generate such revenue unless and until clinical development and regulatory approval are achieved [sec_mda · as of 2026-08-13].
- Cash runway only into Q1 2027, with no committed external funding source, requiring future financing through equity, debt, or partnerships [sec_mda · as of 2026-08-13].
- Significant ongoing expenses for preclinical studies, clinical trials, manufacturing, and regulatory activities [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Cash runway into Q1 2027
“restricted cash and marketable securities will fund our planned operations into the first quarter of 2027.”
SEC MD&A · August 13, 2026
No product revenue until regulatory approval
“We will not generate revenue from commercially approved product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates.”
SEC MD&A · August 13, 2026
CHOICE platform and pipeline
“Employing our proprietary selection technology and discovery and development platform (CHOICE), we have developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates.”
SEC MD&A · August 13, 2026
Multiple tumor types and delivery routes
“These provide potential utility in multiple tumor types in both the monotherapy and combination therapy settings, via physician-preferred administration techniques, including regional (e.g., intraperitoneal), local and systemic (e.g., intravenous) delivery routes.”
SEC MD&A · August 13, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · olvi-vec — Phase 2 Readout: olvi-vec — Topline results from a Phase 2 study of olvi-vec will provide initial efficacy and safety data.
- 2027-12-01 · Phase3_Topline — Phase 3 Topline: A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-double — Topline results from a randomized Phase 3 study of olvi-vec followed by platinum-double chemotherapy will be a key regulatory milestone.
Risks & what to watch (4)›
Key risks
- Cash runway limited — Cash of $9.2M as of 2026-06-30 funds operations only into Q1 2027; may need additional financing sooner [sec_mda · as of 2026-08-13].
- No approved products or revenue — No revenue from product sales; depends on successful clinical development and regulatory approval [sec_mda · as of 2026-08-13].
- Clinical and regulatory uncertainty — Costs and outcomes of preclinical studies, clinical trials, and regulatory reviews are uncertain [sec_mda · as of 2026-08-13].
- Dependence on external financing — No committed external funding; future capital needs may require equity, debt, or partnership deals [sec_mda · as of 2026-08-13].
What to watch
- Phase 2 topline data for olvi-vec expected around 2026-12-31 [catalyst].
- Phase 3 topline data for olvi-vec followed by platinum-double expected around 2027-12-01 [catalyst].
- Cash position and any new financing or partnership announcements [sec_mda · as of 2026-08-13].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run GENELUX Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GENELUX Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
8.5 months
D/E 0.63 · 0% dilution
Lead: Phase 1/Phase 2
2 candidates
2 upcoming, next in ~123d
0 buys · 15 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
69
Total value held
$23.5M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 3,390,960 | $8.2M |
| woodward diversified capital, llc | 2,117,183 | $5.9M |
| geode capital management, llc | 453,761 | $1.1M |
| blackrock, inc. | 405,872 | $982K |
| bank of america corp /de/ | 323,865 | $784K |
| flputnam investment management co | 280,904 | $680K |
| vanguard fiduciary trust co | 251,610 | $609K |
| northern trust corp | 164,456 | $398K |
| provident wealth management, llc | 155,670 | $377K |
| state street corp | 145,850 | $353K |
Showing top 10 of 69 institutional holders of GENELUX Corp. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 6.9%
- Days to cover
- 12.2
- Shares short
- 3,020,978
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GNLX short interestGovernance
Frequently asked questions
What is the AI investment thesis for GENELUX Corp?
Genelux Corp (GNLX) is a clinical-stage biopharmaceutical company developing oncolytic vaccinia virus (VACV) immunotherapies for multiple tumor types, leveraging its proprietary CHOICE platform.
What is GENELUX Corp's lead drug candidate?
GENELUX Corp's most advanced tracked candidate is olvi-vec (Phase 1/Phase 2) for Ovarian Cancer.
What is GENELUX Corp's next catalyst?
GENELUX Corp's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: olvi-vec" — expected December 31, 2026.
Who is the CEO of GENELUX Corp?
Mr. Thomas D. Zindrick J.D. is the chief executive officer of GENELUX Corp (GNLX).
Where is GENELUX Corp headquartered?
GENELUX Corp (GNLX) is headquartered in Westlake Village, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.